Saturday, January 12, 2019 8:45:50 AM
Here's my questions/concerns:
Given the fact we know Cannabix hit a value of nearly 300M USD without a working handheld device, what do you think is a fair price to sell off Btec FAIMS after shareholders helped ($) push the tech just as far as Cannabix?
Also, would you say Yost is now technically working on NASH to the future benefit ($) of Owlstone Medical? Hence, the reason for Yost's recent appointment to Owlstone's board of advisors?
If Btec sold FAIMS for 300M USD, would that effectively increase the current outstanding share price to 300M USD + 49,000,000 shares = $6+ ,or would you expect a less transparent mathematical/monetary deal to unfold?
IMO, 300M USD would be a low ball number to buyout FAIMS medical. I simply do not see Owlstone Medical coming up with the cash to make a reasonable offer.
Let's keep in mind that Kal is selling the idea that Nash Pharmaceuticals is in a space where 100's of Millions of dollars get thrown around everyday. be it partnerships or buyouts.
Meanwhile...we know FAIMS is all we have relied on here to payoff big for investors. Were not here to simply wait and wait and wait on Nash Pharma. Soon...the revealing of Cannabix's device will provide proof Breathtec has also arrived - Research Use Only Handheld Device(s) - Bring It On Kal!
Peace,
/////AMG
FEATURED Element79 Gold Corp Reports Exceptionally High-Grade Results from Lucero • May 14, 2024 7:00 AM
VAYK Added New Manager for Expansion into $64 Billion Domestic Short-term Rental Market • VAYK • May 14, 2024 9:00 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM